Fruth Investment Management Sells 50 Shares of Eli Lilly and Company (NYSE:LLY)

Fruth Investment Management trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,935 shares of the company’s stock after selling 50 shares during the period. Fruth Investment Management’s holdings in Eli Lilly and Company were worth $1,505,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Lipe & Dalton bought a new position in Eli Lilly and Company during the 4th quarter valued at $26,000. Core Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the period. Tidemark LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $29,000. Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company in the 1st quarter worth about $40,000. Finally, Frank Rimerman Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $37,000. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now owns 97,299,772 shares in the company, valued at approximately $89,059,454,309.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 858,742 shares of company stock valued at $735,573,781. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Stock Down 0.9 %

Shares of NYSE LLY traded down $8.61 during midday trading on Thursday, reaching $898.10. 3,078,367 shares of the company’s stock traded hands, compared to its average volume of 2,667,176. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock’s 50 day simple moving average is $824.60 and its 200-day simple moving average is $746.69. Eli Lilly and Company has a one year low of $434.34 and a one year high of $918.50. The company has a market cap of $853.56 billion, a price-to-earnings ratio of 132.27, a P/E/G ratio of 1.98 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the firm earned $1.62 earnings per share. On average, analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.